Cochrane · systematic review · CD003715
Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease
Akobeng, AK, Zhang, D, Gordon, M, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 2 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
5‐ASA compared to placebo for maintenance of medically‐induced remission in Crohn's disease
Population: patients with maintenance of medically‐induced remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse, drop‐outs classed as relapse, grouped by length of 5‐ASA vs placebo | RR 0.98 [0.91, 1.07] | 11 studies · 2014 participants | Moderate Downgraded: risk of bias |
Relapse, drop‐outs classed as relapse, grouped by length of 5‐ASA vs placebo | RR 0.99 [0.8, 1.23] | 1 study · 161 participants | Low Downgraded: risk of bias, imprecision |
Relapse, drop‐outs classed as relapse, grouped by length of 5‐ASA vs placebo | RR 1.07 [0.86, 1.33] | 1 study · 132 participants | Moderate Downgraded: imprecision |
Adverse events 5‐ASA vs placebo | RR 1.05 [0.95, 1.17] | 10 studies · 1814 participants | Low Downgraded: risk of bias, inconsistency |
Withdrawals due to adverse events 5‐ASA vs placebo | RR 1.11 [0.88, 1.38] | 10 studies · 1833 participants | Low Downgraded: imprecision, inconsistency |
Serious adverse events 5‐ASA vs placebo | RR 1.43 [0.24, 8.44] | 3 studies · 576 participants | Low Downgraded: imprecision |